Recently, we established that irisin was a better predictor for the renoprotective effect of the SGLT2 inhibitor dapagliflosin in diabetics with chronic symptomatic HF, regardless of its phenotypes [30]. This evidence concerns the gene SLC5A2 and hydrops fetalis.